A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential ...

Abbvie ((ABBV)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie, in collaboration with Hoffmann-La Roche and the German CLL Study Group, has completed a Phase III clinical trial titled ‘A ...

A fixed-duration, three-drug regimen for chronic lymphocytic leukemia (CLL) achieved deep and durable remissions lasting for up to 7 years, according to updated results from a prospective study.

Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...

AbbVie and Johnson & Johnson’s Imbruvica is under increasing pressure from new in-class competitors, but the pair hopes a new combination and longer-term data could help consolidate its lead in ...

The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery. People with chronic lymphocytic leukemia (CLL) are at a higher risk of contracting ...

James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma (PCNSL), stating the company ...

FOR YOUR REFERENCE: What Are Clinical Trials? Clinical trials determine whether a drug works in humans and whether it is safe and effective. For a drug to be approved for use, the Food and Drug ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...

BeiGene’s argument for its BTK inhibitor Brukinsa is that it’s a better drug than AbbVie and Johnson & Johnson’s first-to-market Imbruvica in terms of both efficacy and safety. Now, it appears to have ...

Lori A. Leslie, MD: We now have 3 covalent BTK [Bruton tyrosine kinase] inhibitors approved in CLL [chronic lymphocytic leukemia]. We talked a bit about the frontline setting, and the ...